junctional sarcoplasmic reticulum protein 1Genealiases: JP-45 · JP45
Q-omics provides the consensus-scored JSRP1 profile across patient tissues and cancer cell-line models. JSRP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, JSRP1 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, JSRP1 RNA expression shows 14,031 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUAD, and ESCA as cancer lineages where JSRP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JSRP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JSRP1 survival associations across molecular data types. JSRP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JSRP1 RNA expression–survival associations across cancer types. High JSRP1 expression shows unfavorable associations in KIRC and UVM, but favorable associations in SKCM, HNSC, LUAD and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for JSRP1 RNA expression.
This table summarizes JSRP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for JSRP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JSRP1 shows higher tumor expression in LUAD, COAD, KIRC, UCEC, BLCA and KICH. The LUAD box plot shows higher JSRP1 RNA expression in tumor versus normal tissue (log2 FC = +1.286, t-test p < 0.001).
This table shows molecular features associated with JSRP1 in patient tissues and cancer cell lines. In patient samples, JSRP1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, JSRP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
